Breast cancer data analyzed by race/ethnic groups to identify differences in diagnosis, prognosis
the ONA take:
According to a new study published in the journal JAMA, researchers from Women's College Hospital in Toronto, Ontario, Canada, have found that race and ethnicity may play a role in the timing of breast cancer diagnosis and the prognosis of the woman's disease.
For the study, researchers sought to investigate whether biological differences in tumor aggressiveness affect differences in early-stage breast cancer diagnosis by ethnicity and race.
They identified 373,563 women diagnosed with stage 1 breast cancer from the Surveillance, Epidemiology and End Results (SEER) database between 2004 and 2011. Women were followed for an average of 40.6 months. Researchers then categorized those women based on race and ethnicity and assessed the biological aggressiveness of the tumors.
They also assessed timing of diagnosis and prognosis based on race/ethnic group. Results showed that Japanese women were more likely to be diagnosed with stage 1 breast cancer than non-Hispanic white women.
In addition, black and South Asian women were more likely to be diagnosed at a later stage than non-Hispanic white women, and black women were more likely to die from stage 1 disease than non-Hispanic white women and South Asian women. Black women were also more likely to die from small-sized tumors than non-Hispanic white women.
When analyzing biological differences in tumor aggressiveness, they found that black women with small-sized tumors were more likely to have triple-negative disease and to present with local and distant metastases than non-Hispanic white women. The researchers note that socioeconomic factors and access to health care may also play a role.
Race and ethnicity may play a role in the timing of breast cancer diagnosis and the prognosis of the woman's disease.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|